Aldeyra (ALDX) announced the resubmission of a new drug application to the FDA for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics Holds Annual Meeting with Key Votes
- Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating
- Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships
- Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities
- Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie